晚期非小细胞肺癌化疗初治患者中循环肿瘤DNA反映肿瘤代谢而非肿瘤负荷:18F-FDG PET/CT研究
本研究在37例化疗初治晚期非小细胞肺癌患者中评估循环肿瘤细胞(CTC)和血浆游离DNA(cfDNA)与18F-FDG PET/CT衍生参数的关系。最大转移灶SUVmax是唯一与基线cfDNA水平独立相关的变量(P=0.016),有代谢活跃骨病灶者cfDNA更高(P=0.02)。cfDNA与肿瘤代谢相关而非代谢肿瘤体积,提示其可能更好反映肿瘤生物学行为或侵袭性而非肿瘤负荷。
要点
- 最大转移灶SUVmax是唯一与基线cfDNA水平独立相关的变量(P=0.016)。
- 有代谢活跃骨病灶的患者亚组cfDNA水平更高(P=0.02)。
- cfDNA与区域或远处代谢肿瘤体积不相关,提示其反映肿瘤生物学行为而非负荷。
核心结论
- cfDNA水平与肿瘤代谢相关,但与区域或远处代谢肿瘤体积不相关,提示cfDNA可能更好反映转移性NSCLC的肿瘤生物学行为或侵袭性而非肿瘤负荷。
研究设计与样本
- 从一项评估治疗前循环肿瘤标志物预后预测作用的试验中纳入79例化疗初治晚期NSCLC患者,本研究招募其中在入组前因临床原因在本机构接受18F-FDG PET/CT者,共37例(24名男性;年龄64.5±8.1岁)。
- 基线采集外周血,用基于过滤的装置按大小分离CTC并形态学鉴定计数;血浆cfDNA用人类端粒酶逆转录酶定量聚合酶链反应定量。
- 计算原发灶(T)、最大淋巴结(N)、最大转移灶(M)的最大径、SUVmax、SUVmean、尺寸整合SUVmax、代谢肿瘤体积和总病灶糖酵解,均对T、N、M独立测量。
- 按转移范围分为局限转移组(M1a或仅因胸外淋巴结的M1b)和播散转移组,并记录代谢活跃骨病灶的有无,比较各亚组。
主要发现
- 最大转移灶SUVmax是唯一与基线cfDNA水平独立相关的变量(P=0.016)。
- 有代谢活跃骨病灶的患者亚组cfDNA水平更高(P=0.02)。
- 局限转移性疾病患者与播散转移性疾病患者比较未显示差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We aimed to evaluate the relationships between circulating tumor cells (CTCs) or plasma cell-free DNA (cfDNA) on one side and a comprehensive range of 18F-FDG PET/CT-derived parameters on the other side in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC). Methods: From a group of 79 patients included in a trial evaluating the role of pretreatment circulating tumor markers as predictors of prognosis in chemotherapy-naive patients with advanced NSCLC, we recruited all those who underwent 18F-FDG PET/CT for clinical reasons at our institution before inclusion in the trial (and thus just before chemotherapy). For each patient, a peripheral blood sample was collected at baseline for the evaluation of CTCs and cfDNA. CTCs were isolated by size using a filtration-based device and then morphologically identified and enumerated; cfDNA was isolated from plasma and quantified by a quantitative polymerase chain reaction using human telomerase reverse transcriptase. The following 18F-FDG PET/CT-derived parameters were computed: maximum diameter of the primary lesion (T), of the largest lymph node (N), and of the largest metastatic lesion (M); SUVmax; SUVmean; size-incorporated SUVmax; metabolic tumor volume; and total lesion glycolysis. All parameters were independently measured for T, N, and M. The associations among CTCs, cfDNA, and 18F-FDG PET/CT-derived parameters were evaluated by multivariate-analysis. Patients were divided into 2 groups according to the presence of either limited metastatic involvement (M1a or M1b due to extrathoracic lymph nodes only) or disseminated metastatic disease. The presence or absence of metabolically active bone lesions was also recorded for each patient, and patient subgroups were compared. Results: Thirty-seven patients recruited in the trial matched our PET-based criteria (24 men; age, 64.5 ± 8.1 y). SUVmax for the largest metastatic lesion was the only variable independently associated with baseline cfDNA levels (P = 0.016). Higher levels of cfDNA were detected in the subgroup of patients with metabolically active bone lesions (P = 0.02), but no difference was highlighted when patients with more limited metastatic disease were compared with patients with disseminated metastatic disease. Conclusion: The correlation of cfDNA levels with tumor metabolism, but not with metabolic tumor volume at regional or distant levels, suggests that cfDNA may better reflect tumor biologic behavior or aggressiveness rather than tumor burden in metastatic NSCLC.
引用
- Morbelli S, Alama A, Ferrarazzo G, et al. Circulating Tumor DNA Reflects Tumor Metabolism Rather Than Tumor Burden in Chemotherapy-Naive Patients with Advanced Non-Small Cell Lung Cancer: 18F-FDG PET/CT Study. J Nucl Med. 2017. PMID: 28450567. doi:10.2967/jnumed.117.193201
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。